Wall Street brokerages expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to post sales of $21.83 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Tandem Diabetes Care’s earnings, with the highest sales estimate coming in at $23.62 million and the lowest estimate coming in at $20.4 million. Tandem Diabetes Care reported sales of $22.99 million during the same quarter last year, which indicates a negative year-over-year growth rate of 5%. The business is scheduled to issue its next quarterly earnings report on Thursday, July 27th.
According to Zacks, analysts expect that Tandem Diabetes Care will report full-year sales of $21.83 million for the current year, with estimates ranging from $101.96 million to $107.5 million. For the next year, analysts anticipate that the firm will post sales of $143.48 million per share, with estimates ranging from $130.99 million to $155.8 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, April 27th. The medical device company reported ($0.75) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by $0.09. Tandem Diabetes Care had a negative return on equity of 220.14% and a negative net margin of 95.57%. The company had revenue of $17.50 million during the quarter, compared to the consensus estimate of $15.72 million. During the same period last year, the firm posted ($0.68) earnings per share. The company’s revenue was down 12.9% compared to the same quarter last year. A number of brokerages have recently issued reports on TNDM. B. Riley reiterated a “neutral” rating and issued a $1.50 price target on shares of Tandem Diabetes Care in a report on Wednesday, May 3rd. Cowen and Company downgraded Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and set a $1.50 price target on the stock. in a report on Monday, April 10th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Piper Jaffray Companies reiterated a “neutral” rating on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Finally, Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a report on Wednesday, March 15th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Tandem Diabetes Care has an average rating of “Hold” and a consensus price target of $4.71.
Tandem Diabetes Care (NASDAQ:TNDM) traded up 0.7366% during midday trading on Friday, reaching $0.9163. The company’s stock had a trading volume of 115,045 shares. The company’s market cap is $45.67 million. The firm has a 50 day moving average price of $1.04 and a 200-day moving average price of $1.98. Tandem Diabetes Care has a 12-month low of $0.87 and a 12-month high of $8.81. In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff bought 1,600,000 shares of the company’s stock in a transaction that occurred on Thursday, March 23rd. The shares were purchased at an average cost of $1.25 per share, for a total transaction of $2,000,000.00. Following the purchase, the chief executive officer now directly owns 2,007,939 shares in the company, valued at $2,509,923.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 37.10% of the stock is owned by insiders.
Tandem Diabetes Care Company Profile Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM) For more information about research offerings from Zacks Investment Research, visit Zacks.com